GlassScriptPhysician profile
Suparna Jain
NPI 1053536458
$9,994.30
in general payments reported to CMS, 2019-2025
22 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $243 · 2021: $245 · 2022: $267 · 2023: $8,124 · 2024: $358 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,741 · Food and Beverage: $1,282 · Travel and Lodging: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,741.19 |
| Food and Beverage | $1,282.47 |
| Travel and Lodging | $860.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $8,417.99 | 2022-2025 | Skytrofa |
| Abbvie INC. | $426.55 | 2019-2025 | |
| Tolmar Pharmaceuticals, INC. | $265.98 | 2020-2022 | |
| Soleno Therapeutics, INC. | $156.69 | 2025 | Vykat Xr |
| Pfizer INC. | $131.79 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $83.00 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $80.95 | 2019 | |
| Sandoz INC. | $57.97 | 2019 | |
| Tolmar, INC. | $55.85 | 2023-2024 | |
| Novo Nordisk INC | $47.41 | 2020-2024 | Sogroya |
| Tandem Diabetes Care, INC. | $43.22 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Neurocrine Biosciences, INC. | $38.04 | 2025 | |
| Glaxosmithkline, LLC. | $32.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $29.08 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $23.89 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $23.61 | 2019 | |
| Genentech USA, INC. | $20.21 | 2019 | |
| Shire North American Group INC | $18.07 | 2019 | |
| Ibsa Pharma INC. | $15.28 | 2021 | |
| Cranial Technologies, INC | $13.93 | 2019 | |
| Phadia US INC. | $12.13 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suparna Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.